about
Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistanceA microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Age-shifting in malaria incidence as a result of induced immunological deficit: a simulation study.Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug TreatmentPopulation pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure.Lack of multiple copies of pfmdr1 gene in Papua New Guinea.Reply to "Parasite Strain, Host Immunity, and Circulating Blood Cells with Dead Parasites: Why Predicting Malaria Parasite Clearance Is Not a Simple Task".Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
P50
Q28472222-CD476825-007C-4522-91FF-8BEB31250641Q33552774-9268833D-E51C-4AD3-8A75-BEFCAB889E88Q33678483-DBD7D80C-94B8-48D8-B683-8E631863BA4BQ35885315-62ACB46C-1E72-4A9F-BD61-D902332D0ACCQ36075783-680BDCE5-B55C-4B4A-8F14-724EEAEA70F7Q36076111-55388BCD-15FE-40B4-BB93-E012A4514FC3Q36558437-A8E2EA2A-1FB4-49F6-B5C9-809CA1C8F453Q36888028-C262F80D-21E6-4D62-996F-0B609B645A9DQ37038270-654F8357-BB79-4CA7-B699-A56C9E7263E0Q37685088-EE608D17-8393-4B67-A632-A140DD7941E5Q38225084-22BDC3C7-556C-4FCF-8185-E6C069D00B84Q39069809-9064A641-6808-4E4C-B42A-C2D9911D80D3Q39069836-7287922C-D404-4648-BFCA-06ABFD653A0CQ42564004-9E9C543F-9293-42DF-8941-9F2415378C1AQ90190621-D4BD51E4-56F9-462E-9B22-A5A0B3842075
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eva Maria Hodel
@ast
Eva Maria Hodel
@en
Eva Maria Hodel
@es
Eva Maria Hodel
@nl
Eva Maria Hodel
@sl
type
label
Eva Maria Hodel
@ast
Eva Maria Hodel
@en
Eva Maria Hodel
@es
Eva Maria Hodel
@nl
Eva Maria Hodel
@sl
prefLabel
Eva Maria Hodel
@ast
Eva Maria Hodel
@en
Eva Maria Hodel
@es
Eva Maria Hodel
@nl
Eva Maria Hodel
@sl
P1053
E-1258-2014
P106
P1153
24402516600
P21
P31
P3829
P496
0000-0001-5821-1685